Abstract Despite the overall clinical success of immune checkpoint inhibitors (ICIs) for treating patients with solid tumors, a large number of patients do not benefit from this approach. Consequently, there is a need for predictive biomarkers. The most prevalent biomarkers such as PD-L1 expression and tumor mutational burden (TMB) do not reliably predict response to […]
Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy.
October 16, 2021
J Exp Clin Cancer Res